TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02569021

Intervention type: DEVICE
Intervention: Biphasic DBS stimulation
Description: The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes as a washout period~3. Biphasic pulse stimulation mode (assessment at 0.5hr)~4. Biphasic pulse stimulation mode (assessment at 1hr)~5. Biphasic pulse stimulation mode (assessment at 2hr)~6. Biphasic pulse stimulation mode (assessment at 3hr)

Intervention type: OTHER
Intervention: Unified Parkinson's Disease Rating Scale
Description: UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.

Intervention type: OTHER
Intervention: Tremor Rating Scale
Description: TRS is used by neurologists to rate the severity of a tremor.

Intervention type: DEVICE
Intervention: Kinesia accelerometer
Description: The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.

Intervention type: DEVICE
Intervention: Trigno wireless system
Description: The Trigno system measure muscle contractions.

Intervention type: OTHER
Intervention: GaitRite walking assessment.
Description: GaitRite records a patients gait pattern.
Study: NCT04397315

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy to the level of canal orifices
Description: Pulp tissue will be removed till the level of canal orifices.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy up to superficial 2-3 mm of pulp chamber
Description: Only superficial pulp from the chamber will be removed
Study: NCT02270801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
Study: NCT00721617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
Study: NCT01962090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Spine Thrust in Seated Position
Description: The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
Study: NCT00721617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral fat load
Description: Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral fat load
Description: Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
Study: NCT02932644

Intervention type: OTHER
Intervention: Baseline serum vitamin D level below 50 nmol/l
Description: There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis

Intervention type: OTHER
Intervention: Baseline serum vitamin D level at or above 50 nmol/l
Description: There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
Study: NCT01878097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Green Dot Bystander Intevention
Description: Intervention allocated at the school level

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Awareness Education
Study: NCT00889980

Intervention type: OTHER
Intervention: Biospecimen banking
Description: SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
Study: NCT02792049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with integrated internal handle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ambu Spur II bag valve mask
Description: Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
Study: NCT03926637

Intervention type: OTHER
Intervention: Multiple Sclerosis Performance Test (MSPT)
Description: Administered as specified in the treatment arm.
Study: NCT03838380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone application
Description: Mobile management group participants were given monitoring system devices including a glucometer with Bluetooth connectivity and an accelerometer to detect physical activity level. The mobile phone application specifically designed for this study was installed at enrollment for the mobile management group to collect clinical data and messages from the patients. The application consisted of four sections: clinical data, nutrition and diet, medication, and messaging system and information. Patients allocated to the mobile management group recorded their blood glucose level and diet via the smartphone application, and health care providers regularly scanned clinical data and messages from patients and sent return messages with tailored medical and nutritional guidance.
Study: NCT00002707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2 IV every 21 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV every 21 days fo 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 IV every 21 days fo 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 IV every 21 days fo 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
Study: NCT00754403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
Study: NCT04141475

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Physiomance acide lipoïque gold
Description: 1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Physiomance acide lipoïque gold
Description: 1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
Study: NCT00790127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQK-1001
Description: HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules administered once a day, orally, for 56 days
Study: NCT02589028

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: premeal protein-enriched bar intake
Description: Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
Study: NCT01195194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRE-TRANSPLANT (PRE=before)
Description: All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRE-TRANSPLANT (PRE=before)
Description: All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL).
Study: NCT02015429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasta meal with added fractions or control with no fractions

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasta meal with added fractions or control with no fractions

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pasta meal with added fractions or control with no fractions
Study: NCT02589028

Intervention type: OTHER
Group type: OTHER
Intervention: breakfast follows by protein bar
Description: Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
Study: NCT02015429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasta meal with added fractions or control with no fractions
Study: NCT04302558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Blood Flow Restriction training
Description: While exercising, an Inflatable cuff, similar to a blood pressure cuff, is applied to the proximal aspect of the femur of the affected lower extremity inflated to occlude blood flow

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: SHAM Exercise Blood Flow Restriction training
Description: While exercising Inflatable cuff, similar to a blood pressure cuff, applied to the proximal aspect of the femur of the affected lower extremity with limited inflation pressure to not occlude blood flow
Study: NCT00852319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpregnancy Care
Description: The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpregnancy Care
Description: The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
Study: NCT02881671

Intervention type: GENETIC
Intervention: genetic blood analysis
Description: patients will undergo a blood sample (15 ml) to analyse their genetic profile

Intervention type: GENETIC
Intervention: genetic blood analysis
Description: patients will undergo a blood sample (15 ml) to analyse their genetic profile

Intervention type: GENETIC
Intervention: genetic blood analysis
Description: patients will undergo a blood sample (15 ml) to analyse their genetic profile

Intervention type: GENETIC
Intervention: genetic blood analysis
Description: patients will undergo a blood sample (15 ml) to analyse their genetic profile
Study: NCT02823418

Intervention type: PROCEDURE
Intervention: No neuraxial labor analgesia
Description: Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.

Intervention type: PROCEDURE
Intervention: Neuraxial labor analgesia
Description: Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
Study: NCT01910389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Study: NCT01930266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Study: NCT01764672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Oral dose 40mg (2 x 20mg)
Study: NCT02100930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GD2 3F8 Monoclonal Antibody
Study: NCT04006704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF FDC placebo
Description: Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF FDC placebo
Description: Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
Study: NCT03025152

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hou Gu Mi Xi
Description: Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
Study: NCT01444898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
Study: NCT02187341

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-HTP
Description: Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
Study: NCT02785146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Huaier Granule is continuously taken three times per day, 20g per time.
Study: NCT01764672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Oral dose 40mg (2 x 20mg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral intake of 2 placebo tablets
Study: NCT02785146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m², ivdrip, D1
Study: NCT01962090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Spine Thrust in Supine Position
Description: The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
Study: NCT02262767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Experimental Pfizer compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Experimental Pfizer compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethobenzamide Hydrochloride
Description: Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethobenzamide Hydrochloride
Description: Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
Study: NCT03772015

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
Study: NCT02785146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², ivdrip, D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium folinate
Description: Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
Study: NCT01910389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for tadalafil
Study: NCT02785146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 400 mg/m², iv, D1; and 2400mg/m², civ, 48h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400 mg/m², iv, D1; and 2400mg/m², civ, 48h
Study: NCT04737980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hcl 0.5% Inj
Description: Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Injection of 8mg (2ml) dexamethasone injectable as admixture
Study: NCT00601146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest computed tomography scan
Description: Once a year for three years
Study: NCT03521661

Intervention type: PROCEDURE
Intervention: Kyphoplasty
Description: Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter
Study: NCT02120352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAB Oral Tablets
Description: White to almost white oval shaped film coated 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAB Oral Tablets
Description: White to almost white oval shaped film coated 30 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
Study: NCT02100930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (granulocyte-macrophage colony-stimulating factor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral isotretinoin